Short Communication
Volume 13:05, 2023

Journal of Sports Medicine & Doping Studies

ISSN: 2161-0673 Open Access

Exploring Anamorelin's Metabolic Effects on Athletes Hepatocytes Using LC-HRMS/MS

Lisuna Lupidi*
Department of Sports Medicine, University of Milan, 20122 Milan, Italy

Introduction

Anamorelin, a Growth Hormone Secretagogue Receptor 1a (GHSR1a) agonist, has garnered attention in recent years due to its potential misuse in the realm of sports. Athletes may seek to exploit its pharmacological properties to gain an unfair advantage, primarily by promoting muscle growth and enhancing performance [1]. Understanding the metabolic effects of anamorelin on hepatocytes is crucial in shedding light on its mechanisms of action and potential for misuse. In this study, we aim to explore the impact of anamorelin on human hepatocytes, employing Liquid Chromatography-High-Resolution Mass Spectrometry (LC-HRMS/MS) to analyse the metabolic changes induced by this compound. By delving into the hepatic metabolism of anamorelin, we hope to provide valuable insights into its potential risks and benefits in the context of athletic performance enhancement [2].

Description

The study involved the utilization of primary human hepatocytes obtained from a well-established in vitro model. These hepatocytes were exposed to varying concentrations of anamorelin, replicating conditions that athletes may encounter when misusing the compound [3]. Following exposure, we meticulously examined the metabolic profile of the hepatocytes using LC-HRMS/MS, a state-of-the-art analytical technique known for its precision and sensitivity in detecting molecular changes Our analysis focused on identifying alterations in the expression of metabolites associated with key hepatic processes such as energy metabolism, lipid metabolism and detoxification pathways. By comparing the metabolic profiles of hepatocytes treated with anamorelin to control groups, we aimed to pinpoint any significant deviations that could indicate potential risks or advantages of using this compound in a sporting context [4,5].

Conclusion

The findings of our study unveil a complex web of metabolic effects induced by anamorelin in athletes' hepatocytes. These effects extend beyond mere muscle growth stimulation, delving into intricate changes within the liver's metabolic machinery. Notably, we observed significant alterations in energy utilization patterns, lipid metabolism and detoxification pathways in response to anamorelin exposure. This study emphasizes the multifaceted nature of anamorelin's impact on athletes' physiology, underlining both its potential benefits in terms of performance enhancement and the potential health risks that may accompany its misuse. As such, it underscores the importance of informed decision-making among athletes and robust monitoring by sports authorities and healthcare professionals. In conclusion, our research underscores the critical need for continued investigation into the metabolic effects of anamorelin and similar compounds, aiming to strike a balance between the pursuit of excellence in sports and the preservation of athletes' health and integrity. Such efforts are pivotal in ensuring that the world of sports remains a fair and safe arena for all athletes.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Wiesing, Urban. "Should performance-enhancing drugs in sport be legalized under medical supervision?." *Sports Med* 41 (2011): 167-176.
2. Reardon, Claudia L. and Shane Creado. "Drug abuse in athletes." *Subst Abus* (2014): 95-105.
3. La Gerche, André and Maria J. Brosnan. "Cardiovascular effects of performance-enhancing drugs." *Circulation* 135 (2017): 89-99.
4. Wang, Guiyun, Heung-Man Lee, Ella Englander and George H. Greeley Jr. "Ghrelin—not just another stomach hormone." *Regul Pept* 105 (2002): 75-81.
5. Pradhan, Geetali, Susan L. Samson and Yuxiang Sun. "Ghrelin: Much more than a hunger hormone." *Curr Opin Clin Nutr Metab Care* 16 (2013): 619.

How to cite this article: Lupidi, Lisuna. "Exploring Anamorelin's Metabolic Effects on Athletes Hepatocytes Using LC-HRMS/MS." *J Sports Med Doping Stud* 13 (2023): 333.

***Address for Correspondence:** Lisuna Lupidi, Department of Sports Medicine, University of Milan, 20122 Milan, Italy, E-mail: lupidi@gmail.com*

Received: 04 September, 2023, Manuscript No. jsmds-23-114931; **Editor Assigned:** 06 September, 2023, PreQC No. P-114931; **Reviewed:** 18 September, 2023, QC No. Q-114931; **Revised:** 23 September, 2023, Manuscript No. R-114931; **Published:** 30 September, 2023, DOI: 10.37421/2161-0673.2023.13.333